Skip to main content

Table 3 Cox regression analyses by HER2 status in 458 women with a primary DCIS

From: The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study

  DCIS
  HER2 positive HER2 negative
  HR (95 % CI) HR (95 % CI)
Ipsilateral Breast Events (IBE)   
BCS (n = 331) (events = 95)   
 Univariate HR (95 % CI) 1.20 (0.78–1.85) (Ref)
aAdjusted HR (95 % CI) 1.27 (0.83–1.96) (Ref)
bAdjusted HR (95 % CI) 1.17 (0.75–1.83) (Ref)
cAdjusted HR (95 % CI) 1.22 (0.76–1.95) (Ref)
BCS, in situ IBEs (events = 49)   
 Univariate HR (95 % CI) 1.63 (0.92–2.89) (Ref)
aAdjusted HR (95 % CI) 1.76 (0.99–3.11) (Ref)
bAdjusted HR (95 % CI) 1.40 (0.77–2.54) (Ref)
cAdjusted HR (95 % CI) 1.65 (0.88–3.11) (Ref)
BCS, invasive IBEs (events = 46)   
 Univariate HR (95 % CI) 0.78 (0.40–1.55) (Ref)
aAdjusted HR (95 % CI) 0.83 (0.42–1.64) (Ref)
bAdjusted HR (95 % CI) 0.87 (0.43–1.75) (Ref)
cAdjusted HR (95 % CI) 0.80 (0.38–1.66) (Ref)
Invasive Breast Cancer Recurrence (IBCR)   
All patients (n = 420) (Events = 102)   
 Univariate HR (95 % CI) 0.60 (0.38–0.94) (Ref)
aAdjusted HR (95 % CI) 0.58 (0.38–0.95) (Ref)
bAdjusted HR (95 % CI) 0.59 (0.37–0.95) (Ref)
cAdjusted HR (95 % CI) 0.59 (0.36–0.98) (Ref)
  1. BCS breast conserving surgery
  2. aAdjusted for radiotherapy
  3. bAdjusted for radiotherapy, age at diagnosis (continuous) and size
  4. cAdjusted for radiotherapy, age at diagnosis and ER